Systematic Evaluation of Efficacy and Safety Qili Qiangxin Capsules in the Treatment of Acute Myocardial Infarction Complicated with Heart Failure

CHEN Yahui; XU Junpeng; ZHU Haiyue; XU Danping; HE Zhiling; WANG Xia

doi:10.14009/j.issn.1672-2124.2020.06.016

您当前的位置：

首页 >

文章列表页 >

Systematic Evaluation of Efficacy and Safety Qili Qiangxin Capsules in the Treatment of Acute Myocardial Infarction Complicated with Heart Failure

更新时间：2022-10-08

- Systematic Evaluation of Efficacy and Safety Qili Qiangxin Capsules in the Treatment of Acute Myocardial Infarction Complicated with Heart Failure
- Vol. 20, Issue 6, Pages: 698-703(2020)
- 作者机构：
  
  1. 广东省中医院心血管科
  2. 广州中医药大学第二临床医学院
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2020.06.016
  CLC： R542.22;R541.6
- Published：2020，
扫描看全文
[1]陈亚辉,徐俊鹏,朱海月,徐丹苹,何志凌,王侠.芪苈强心胶囊治疗急性心肌梗死并发心力衰竭疗效和安全性的系统评价[J].中国医院用药评价与分析,2020,20(06):698-703.

CHEN Yahui, XU Junpeng, ZHU Haiyue, et al. Systematic Evaluation of Efficacy and Safety Qili Qiangxin Capsules in the Treatment of Acute Myocardial Infarction Complicated with Heart Failure. [J]. 20(6):698-703(2020)
[1]陈亚辉,徐俊鹏,朱海月,徐丹苹,何志凌,王侠.芪苈强心胶囊治疗急性心肌梗死并发心力衰竭疗效和安全性的系统评价[J].中国医院用药评价与分析,2020,20(06):698-703. DOI： 10.14009/j.issn.1672-2124.2020.06.016.

CHEN Yahui, XU Junpeng, ZHU Haiyue, et al. Systematic Evaluation of Efficacy and Safety Qili Qiangxin Capsules in the Treatment of Acute Myocardial Infarction Complicated with Heart Failure. [J]. 20(6):698-703(2020) DOI： 10.14009/j.issn.1672-2124.2020.06.016.

摘要

目的:系统评价芪苈强心胶囊治疗急性心肌梗死（acute myocardial infarction

AMI）并发心力衰竭（heart failure

HF）的临床疗效和安全性。方法:检索2019年8月前公开发表的芪苈强心胶囊治疗AMI并发HF的中英文随机对照试验（对照组患者采用常规西医治疗;研究组患者在常规西医治疗基础上加用芪苈强心胶囊治疗）

依照纳入与排除标准筛选文献

利用Cochrane偏倚风险工具评估方法学质量后进行荟萃分析（Meta分析）。结果:共纳入10篇文献

均为中文文献

涉及1 048例患者

其中研究组530例

对照组518例。Meta分析结果显示

研究组患者的临床疗效明显优于对照组（RR=1. 42

95%CI=1. 21～1. 67

Z=4. 23

P<0. 000 1）

N末端B型脑钠肽前体水平改善情况明显优于对照组（SMD=-2. 02

95%CI=-3. 13～-0. 91

P=0. 000 4）

左心室射血分数（MD=7. 04

95%CI=5. 10～8. 98

P<0. 000 01）、左心室舒张末期内径（MD=-0. 94

95%CI=-1. 46～-0. 43

P<0. 000 01）和左心室收缩末期内径（MD=-4. 18

95%CI=-5. 52～-2. 84

P<0. 000 01）改善情况明显优于对照组

6分钟步行试验距离明显长于对照组（MD=42. 68

95%CI=23. 92～61. 44

P<0. 000 01）

上述差异均有统计学意义;两组患者均未见严重不良事件发生。结论:芪苈强心胶囊对于改善AMI并发HF的临床症状及心功能是安全有效的

但其远期预后仍需更多临床研究。

Abstract

OBJECTIVE: To systematically evaluate the clinical efficacy and safety of Qili Qiangxin capsules in the treatment of acute myocardial infarction（ AMI） complicated with heart failure（ HF）. METHODS: Chinese and English randomized controlled trials of Qili Qiangxin capsules in the treatment of HF complicated with AMI（ the control group was treated with conventional western medicine

while the study group received Qili Qiangxin capsules in addition to conventional western medicine） published before Aug. 2019 were retrieved. The literature was screened according to inclusion and exclusion criteria

and the Cochrane Bias Risk Tool was used to assess methodological quality for Meta analysis. RESULTS: Totally 10 clinical studies were collected

which were all Chinese literature

1 048 patients were involved

including 530 cases in the study group and 518 cases in the control group. Meta analysis showed that the clinical efficacy of the study group was significantly better than that of the control group（ RR = 1. 42

95% CI = 1. 21-1. 67

Z = 4. 23

P<0. 000 1）

the improvement of N-terminal B brain natriuretic precursor level was significantly better than that of the control group（ SMD =-2. 02

95% CI =-3. 13--0. 91

P = 0. 000 4）

the improvement of left ventricular ejection fraction（ MD = 7. 04

95% CI = 5. 10-8. 98

P < 0. 000 01）

left ventricular end-diastolic internal diameter（ MD =-0. 94

95% CI =-1. 46--0. 43

P < 0. 000 01） and left ventricular end-systolic internal diameter（ MD=-4. 18

95%CI=-5. 52--2. 84

P<0. 000 01） were better than those of the control group

6 minutes walking test distance was significantly longer than that of the control group（ MD = 42. 68

95% CI = 23. 92-61. 44

P<0. 000 01）

the above differences were statistically significant. No severe adverse drug reactions were seen in either group. CONCLUSIONS: Qili Qiangxin capsules are safe and effective for improving the clinical symptoms and cardiac function of AMI complicated with HF

but its long-term prognosis still needs more clinical research.

关键词

芪苈强心胶囊急性心肌梗死心力衰竭Meta分析

Keywords

Qili Qiangxin capsulesAcute myocardial infarctionHeart failureMeta analysis

references

查看原文

Views

102

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Systematic Review on Comparison of Efficacy Between Sacubitril Valsartan and Renin-Angiotensin-Aldosterone System Blockers in the Treatment of Heart Failure Complicated with Renal Insufficiency

Effects of Ticagrelor on Serum Uric Acid and Creatinine Levels in the Treatment of Patients with Acute Myocardial Infarction

A Rapid Health Technology Assessment of Ivabradine Hydrochloride in the Treatment of Heart Failure

Effect of Shenmai Injection on Heart Function,Serum N-Terminal B-Type Natriuretic Peptide and Hypersensitive Cardiac Troponin T in Elderly Patients with Advanced Breast Cancer at Heart Failure Stage

Related Author

XIAO Youwen

FU Yixing

BAO Yongqiang

DONG Jianhua

PAN Hongxia

HU Xiang

LI Qianqian

LI Bojiang

Related Institution

Dept.of Nephrology, Leshan People’s Hospital

Dept.of Pediatric Respiratory Medicine, Chengdu Women’s and Children’s Central Hospital

Dept.of Cardiology, the Third Affiliated Hospital of Soochow University

Dept.of Pharmacy, the Third Affiliated Hospital of Soochow University

the First Affiliated Hospital of Nanjing Medical University

⁰